Research Articles Library
Literature Analysis Tools
Advanced Search
Filter by PMID, year, source, DOI and other criteria
Literature Analysis
Analyze research trends and hotspots
Batch Export
Export search results to Excel/PDF
Gut microbiota: the pathogenetic bridge between inflammatory bowel disease and metabolic-associated steatotic liver disease
Publication Year: 2025 Source: Expert Rev Gastroenterol Hepatol PMID: 39907629
No Abstract
Letter to the editor: "Cardiovascular magnetic resonance reveals myocardial involvement in patients with active stage of inflammatory bowel disease"
Publication Year: 2025 Source: Clin Res Cardiol PMID: 39907753 DOI: 10.1007/s00392-025-02605-8
No Abstract
[Inflammatory bowel diseases-Part 2]
Publication Year: 2025 Source: Inn Med (Heidelb) PMID: 39907766
No Abstract
TL1A Inhibition in Inflammatory Bowel Disease: A Pipeline Review
Publication Year: 2025 Source: BioDrugs PMID: 39907869 DOI: 10.1007/s40259-025-00706-4
Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), remains challenging to manage, with a substantial proportion of patients not responding to conventional therapies or developing complications. The tumor necrosis factor (TNF) superfamily member TL1A has emerged as an important player in the pathogenesis of IBD, influencing …
Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature Review
Publication Year: 2025 Source: Adv Ther PMID: 39907897
Sandoz-adalimumab (SDZ-ADL; Hyrimoz((R)), GP2017) is an adalimumab (ADL) biosimilar approved for the treatment of immune-mediated inflammatory diseases. Here, we review the available literature on SDZ-ADL from controlled and real-world evidence studies. A literature search was carried out to identify articles published up to July 2023 reporting data on efficacy, safety, …
The influence of stress, coping mechanisms and psychological symptoms on inflammatory bowel disease activity: A retrospective case-control analysis
Publication Year: 2025 Source: Indian J Gastroenterol PMID: 39907920 DOI: 10.1007/s12664-024-01714-y
BACKGROUND AND OBJECTIVES: Psychological stress is widely recognized as a key factor that can initiate or aggravate symptoms in patients with inflammatory bowel disease (IBD). This research was aimed at examining the influence of stressors, coping mechanisms and psychological symptoms on disease activity in patients with Crohn's disease (CD) and …
The shared mechanism of barrier dysfunction in ulcerative colitis and Alzheimer's disease: DDIT4/IL1β neutrophil extracellular traps drive macrophages-mediated phagocytosis
Publication Year: 2025 Source: Int Immunopharmacol PMID: 39908802
Ulcerative colitis (UC) and Alzheimer's disease (AD) share a common etiology as inflammatory diseases characterized by barrier deterioration. The aim of this study is to elucidate how neutrophil extracellular traps (NETs), serving as a comorbid etiological factor, can trigger the dysfunction in both the intestinal barrier and blood-brain barrier (BBB). …
Colon-targeted dual-coating MOF nanoparticles for the delivery of curcumin with anti-inflammatory properties in the treatment of ulcerative colitis
Publication Year: 2025 Source: Colloids Surf B Biointerfaces PMID: 39908958
The inflammatory response is the core mechanism of the pathogenesis and symptoms of ulcerative colitis (UC), and inhibiting inflammation is a promising therapeutic approach to improving UC. Curcumin is considered a potential treatment for UC due to its significant anti-inflammatory and antioxidant effects. However, its bioavailability in the post-oral administration …
Extended Risankizumab Treatment in Patients With Crohn's Disease Who Did Not Achieve Clinical Response to Induction Treatment
Publication Year: 2025 Source: Clin Gastroenterol Hepatol PMID: 39909280
BACKGROUND & AIMS: The efficacy and safety of extended treatment with risankizumab (RZB), an anti-interleukin-23 p19 monoclonal antibody, were evaluated in patients with moderate to severe Crohn's disease (CD) who did not achieve clinical response to 12 weeks (W) RZB induction treatment ('initial nonresponders'). METHODS: Initial nonresponders to intravenous (IV) …
Fecal calprotectin, intestinal ultrasound, and their combination for the diagnosis of inflammatory bowel disease
Publication Year: 2025 Source: Clin Res Hepatol Gastroenterol PMID: 39909306 DOI: 10.1016/j.clinre.2025.102549
BACKGROUND: We aimed to evaluate the diagnostic accuracy of fecal calprotectin (FC) and intestinal ultrasound (IUS), independently and in combination, as screening tools for adults with suspected IBD to reduce the number of unnecessary endoscopic procedures. METHODS: We conducted a retrospective monocentric study that included consecutive adult patients with (i) …
Need more literature?
The current database contains 98453 research articles. If you need to search for more literature or perform AI analysis, please use our knowledge acquisition module or explore external literature resources.
External Resources: Access comprehensive literature databases worldwide